Issa, Ghayas C.

University Health Network · Seoul National University · Chinese Academy of Medical Sciences & Peking Union Medical College · Seoul National University Hospital · University of Chicago · Jena University Hospital · Institute of Hematology & Blood Diseases Hospital · State Key Laboratory of Experimental Hematology · Eulji University Uijeongbu Eulji Medical Center · The University of Adelaide · Charité – Universitätsmedizin Berlin

7 papers on CoChatORCID 0000-0002-4339-8683

Most cited papers

Verified
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
Hochhaus, A., Wang, J., Kim, D.-W., Kim, D. D. H., Mayer, J., Goh, Y.-T., le Coutre, P., Takahashi, N., Kim, I., Etienne, G., et al. (2024) · New England Journal of Medicine
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research
Cited by 171
Verified
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
Bidikian, A., Kantarjian, H., Jabbour, E., Short, N. J., Patel, K., Ravandi, F., Sasaki, K., & Issa, G. C. (2022) · Blood Cancer Journal
Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research
Cited by 55
Verified
Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor
Bidikian, A., Jabbour, E., Issa, G. C., Short, N. J., Sasaki, K., & Kantarjian, H. (2023) · American Journal of Hematology
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research
Cited by 32
Verified
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results
Gener-Ricos, G., Haddad, F. G., Sasaki, K., Issa, G. C., Skinner, J., Masarova, L., Borthakur, G., Alvarado, Y., Garcia-Manero, G., Jabbour, E., et al. (2023) · Clinical Lymphoma Myeloma and Leukemia
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research
Cited by 30
Verified
The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors
Jabbour, E. J., Sasaki, K., Haddad, F. G., Issa, G. C., Garcia‐Manero, G., Kadia, T. M., Jain, N., Yilmaz, M., DiNardo, C. D., Patel, K. P., et al. (2023) · American Journal of Hematology
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research
Cited by 22
Verified
Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
Cortes, J. E., Hochhaus, A., Hughes, T. P., Wang, J., Kim, D.-W., Kim, D. D. H., Mayer, J., Goh, Y. T., le Coutre, P., Etienne, G., et al. (2024) · Blood
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research
Cited by 7
Verified
The presence of additional cytogenetic abnormalities ( ACAs ) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia
Haddad, F. G., Sasaki, K., Issa, G. C., Jabbour, E., & Kantarjian, H. (2024) · American Journal of Hematology
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research
Cited by 4

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.